Two Cases of Type 2 Diabetes Treated With Abiraterone Acetate/steroid Combination Therapy for Prostate Cancer Requiring Insulin Treatment

DOI
  • Ueda Teruhisa
    Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital
  • Nakaguchi Hironobu
    Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital
  • Akesaka Kazuyuki
    Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital
  • Ono Keizo
    Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital
  • Ebisui Osamu
    Department of Diabetes and Endocrinology, Ehime Prefectural Central Hospital
  • Matsuura Bunzo
    Department of Lifestyle-related Medicine and Endocrinology, Ehime University Graduate School of Medicine

Bibliographic Information

Other Title
  • 前立腺癌に対するアビラテロン・ステロイド併用療法によりインスリン治療が必要となった2型糖尿病2症例

Search this article

Description

<p>Case 1 involved a 69-year-old man with prostate cancer with bone metastasis. Abiraterone acetate/steroid combination therapy was started, after which the patient noticed symptoms of hyperglycosemia. Within 1 month, he was hospitalized due to a glycated hemoglobin (HbA1c) level of 8.5 % and a random blood glucose level that had worsened to 400 mg/dL. Case 2 involved an 82-year-old man in whom abiraterone acetate/steroid combination therapy had been started after anti-androgen therapy proved ineffective for prostate cancer. During treatment, his glucose tolerance was not evaluated; he therefore had no subjective symptoms. He was hospitalized for ketosis and an HbA1c level of 9.5 % identified during a checkup performed 9 months after starting the medication. Although no significant decrease in the endogenous insulin level was observed in either case, insulin treatment and glucagon-like peptide 1 (GLP-1) receptor agonist combination were used to correct the hyperglycemia. Abiraterone acetate became available for the treatment of prostate cancer in Japan in 2014. Its use in combination with steroids requires caution due to the risk of exacerbation. We experienced two cases with impaired glucose tolerance after the initiation of treatment and report the situation of their use in our hospital with a review of the literature.</p>

Journal

Keywords

Details 詳細情報について

  • CRID
    1390282763131114624
  • NII Article ID
    130007684561
  • DOI
    10.11213/tonyobyo.62.398
  • ISSN
    1881588X
    0021437X
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top